comparemela.com

Page 7 - Cysview Hexvix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

New study demonstrates that tumor removal in the outpatient setting is as good as TURBT under general anesthesia

/PRNewswire/ Photocure ASA, The Bladder Cancer Company, announces the publication of first results from the Laser III clinical study in the medical journal,.

United statesNew zealandGregersg hermannErik dahlDan schneiderDavid moskowitzCysview hexvixHerlev gentofteHexvix cysviewCorporate communications norwayBladder cancer companyAmerican cancer societyOslo stock exchangeCapital regionEuropean urologyLead investigator

Photocure Partner Asieris announces coverage of Hexvix by the Lecheng Global Specialty Drug Insurance

Press release - Oslo, Norway, September 15, 2022: Photocure ASA , The Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has communicated today on the inclusion of Hexvix®. | September 15, 2022

Hainan provinceUnited statesNew zealandErik dahlDan schneiderDavid moskowitzCysview hexvixHexvix cysviewAsieris pharmaceuticalsBladder cancer companyCorporate communicationsBoao lecheng international medical tourism pilot zoneNational medical products administrationAmerican cancer societyOslo stock exchangeGlobal specialty drug insurance

Photocure Collaborations at EAU Support the Latest Advancements in Bladder Cancer Technology

High-definition blue light cystoscopic imaging showcased at the European Association of Urology (EAU).

United statesNew zealandNoord hollandPrnewswire photocureKarl storzDavid moskowitzviceDan schneiderpresidentErik dahlcfophotocure asatelRichard wolfCysview hexvixCeophotocure asaemailHexvix cysviewPhotocure asaphotocurePhotocure hexvixRelationsphotocure asatelSusanne strauss

Positive Data from the Danish National Patient Registry presented at the 2022 Nordic Urologisk Forening (NUF) Congress in Helsinki

/PRNewswire/ Photocure ASA (OSE: PHO) announces that positive data from a Danish population registry study featuring nearly 10,000 bladder cancer patients.

United statesNew zealandEteläuomen läiPrnewswire photocureErik dahlNordisk urologisk foreningDan schneiderDavid moskowitzCysview hexvixHexvix cysviewBladder cancer companyDanish bladder cancer groupDepartment of urology aarhus university hospitalCorporate communications norwayDanish national patient registryNordic urothelial cancer research group

Photocure: Positive Data from the Danish National Patient Registry presented at the 2022 Nordic Urologisk Forening (NUF) Congress in Helsinki

Lower rates of bladder cancer recurrence and progression demonstrated in clinics with a high level of blue light cystoscopy (BLC) use in primary patients Photocure sponsor of the Residents

United statesNew zealandEteläuomen läiPrnewswire photocureErik dahlNordisk urologisk foreningDan schneiderDavid moskowitzCysview hexvixHexvix cysviewBladder cancer companyDanish bladder cancer groupDepartment of urology aarhus university hospitalCorporate communications norwayDanish national patient registryNordic urothelial cancer research group

vimarsana © 2020. All Rights Reserved.